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Rudolf Ludwig Carl Virchow (13 October 1821 - 5 September 1902) 
was a German physician, anthropologist, pathologist, prehistorian, 
biologist, writer, editor and politician who is widely regarded as the 
the ‘father of modern pathology’ and was affectionately called the 
‘Pope of medicine’ by his friends. His investigation of the 1847 - 
1848 typhus epidemic laid the foundation for the establishment of 
public health as a discipline in Germany, and paved his political 
and social careers. He famously coined the aphorism: ‘Medicine 
is a social science, and politics is nothing else but medicine on a 
large scale.’ 
Virchow was the first to describe and christen conditions such as 
thrombosis, embolism, leukaemia, chordoma and ochronosis. He was 
also the first to correctly describe the mechanisms of the development 
of cancers. He coined many biological and medical terms in everyday 
use, including chromatin, neuroglia, agenesis, parenchyma, osteoid, 
amyloid degeneration and spina bifida. There are many terms, such 
as Virchow’s triad, Virchow’s node, Virchow-Seckel syndrome and 
Virchow-Robin spaces, which are named after him. He developed 
the first systematic method of autopsy and introduced hair analysis 
in pathological and forensic investigation. His description of the life 
cycle of the roundworm, Trichinella spiralis, established the practice 
of meat inspection. 
Virchow’s triad describes the three broad categories of factors 
that are thought to contribute to thrombosis: hypercoagulability, 
haemodynamic changes and endothelial injury. Interestingly, the 
elements comprising Virchow’s triad were neither proposed by 
Virchow, nor did he ever suggest a triad to describe the pathogenesis 
of venous thrombosis. In fact, it was decades following his death 
before consensus was reached proposing that thrombosis is the 
result of alterations in blood flow, vascular endothelial injury or 
alterations in the constitution of the blood. However, our current 
understanding of the pathophysiology of thrombosis is similar to 
his proposed description of the mechanism of embolism, published 
in 1856.[1] 
Pregnancy and the puerperium are well-established risk factors 
for venous thromboembolism (VTE). The overlap with symptoms 
of pregnancy may impair clinical suspicion, making the diagnosis 
of VTE more challenging. VTE can manifest during pregnancy 
as an isolated lower-extremity deep-vein thrombosis (DVT), or a 
clot can break off from the lower extremities and travel to the lung 
to present as a pulmonary embolus (PE), the 7th leading cause of 
maternal mortality and responsible for 9% of maternal deaths.[2] 
The detection of DVT during pregnancy is critical to prevent deaths 
from PE. Pregnancy-related mortality has the largest racial disparity 
among the maternal and child health indicators: black women have 
a 3 - 4 times higher pregnancy-related mortality ratio than white 
women. Although the reasons for this cannot be directly attributed 
to increased rates of VTE, the number of deaths from this condition 
are higher in black than in white women.[2] 
A risk model for VTE within the first 6 weeks postpartum has 
been developed and externally validated, based upon two large 
European cohorts.[3] Among the many factors that contribute to 
the model, those associated with the highest risk were emergency 
caesarean section, stillbirth, varicose veins, pre-eclampsia/eclampsia, 
postpartum infection and comorbidities. Further validation is needed 
to confirm these results. The mechanisms leading to VTE in 
pregnancy are included in Table 1.
In this issue of CME, there are two articles. The first article by 
Wessels[4] on pregnancy-associated VTE reviews the epidemiology, 
risk factors, pathophysiology, approach to initial assessment, diagnosis 
and management of VTE. The guidance is appropriate for local 
practice, and situations where specific hypercoagulation problems 
manifest, are reviewed. Further, the appropriate management of 
labour and neuraxial anaesthesia is also discussed. The author 
concludes that, although managing VTE in the pregnant patient is 
complex, a team approach taking all factors in the individual patient 
into consideration is essential.
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
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Table 1. Pathophysiology of venous thromboembolism in 
pregnancy
Stasis due to changes in venous capacitance and compression of 
large veins by the gravid uterus
Endothelial injury at uteroplacental interface
Hypercoagulability due to increases in coagulation factors I, II, 
VII, VIII, IX and X, along with a decrease in protein S, resistance 
to activated protein C and abnormal expression of plasminogen 
activator inhibitors 1 and 2
Timing during pregnancy
• Factors that increase the risk of VTE antepartum include 
multiple births, varicose veins, inflammatory bowel disease, 
urinary tract infection, diabetes, BMI ≥30 kg/m2, increased 
maternal age (≥35 years), and hospitalisation for non-delivery 
reasons (particularly if >3 days)
• Factors that increase the risk of VTE postpartum include 
caesarean section, medical comorbidities, BMI ≥30 kg/m2, young 
gestational age (<36 weeks), obstetric haemorrhage, stillbirth, 
increased maternal age (≥35 years), hypertension, smoking, 
eclampsia or pre-eclampsia and postpartum infection
Anatomical location of DVT
• Left lower-extremity DVT due to increased venous stasis in the 
left leg related to compression of the left iliac vein by the right 
iliac artery, coupled with compression of the inferior vena cava 
by the gravid uterus
• Pelvic vein DVT more likely to be associated with PE
Inherited thrombophilias (3 times higher risk of VTE in pregnant 
women with factor V Leiden; 8 times increased risk of VTE in 
pregnant women with inherited deficiency of antithrombin III, 
protein S or protein C; and 5% higher risk of VTE in pregnant 
women with antiphospholipid syndrome)
Changes in systemic haemodynamics (heart rate, cardiac output, 
cardiac function, maternal posture, multiple gestation, blood 
pressure and vascular resistance, and changes to blood vessels and 
flow)
Uteroplacental circulation
VTE = venous thromboembolism; BMI = body mass index; DVT = deep-vein thrombosis; 
PE = pulmonary embolism. 
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The second article, by Menard et al.,[5] reviews transfusion thresholds 
in clinical practice. It provides a practical and evidence-informed 
approach to the transfusion of red blood cells and platelets in 
commonly encountered clinical settings. While transfusion 
improves oxygen delivery in patients with anaemia, injudicious 
use of red blood cells may be associated with complications, 
including infection, allergic and immune reactions, volume 
overload, hyperkalaemia and iron overload. Even though numerous 
studies have shown an association between anaemia and increased 
mortality, it is not clear whether aggressive correction of anaemia 
improves mortality. The appropriate and evidence-based use of 
red blood cell and platelet transfusions is reviewed. The authors 
conclude that, while transfusion of blood products is one of the most 
routinely administered interventions in healthcare, blood products 
are a limited resource and transfusion practices need to be carefully 
scrutinised. The authors remind us that a one-size-fits-all approach 
in clinical practice has appropriately fallen 
by the wayside. 
It is our hope that the readers of CME 
will find these articles to be of utility in 
enhancing their clinical practice. 
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